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Purpose:  Norrie  disease  (ND),  a  rare  X-linked  recessive  disorder,  is  characterized  by  congenital  blindness  and,
occasionally, mental retardation and hearing loss. ND is caused by the Norrie Disease Protein gene (NDP), which codes
for norrin, a cysteine-rich protein involved in ocular vascular development. Here, we report a novel mutation of NDP that
was identified in a Chinese family in which three members displayed typical ND symptoms and other complex phenotypes,
such as cerebellar atrophy, motor disorders, and mental disorders.
Methods: We conducted an extensive clinical examination of the proband and performed a computed tomography (CT)
scan of his brain. Additionally, we performed ophthalmic examinations, haplotype analyses, and NDP DNA sequencing
for 26 individuals from the proband’s extended family.
Results: The proband’s computed tomography scan, in which the fifth ventricle could be observed, indicated cerebellar
atrophy. Genome scans and haplotype analyses traced the disease to chromosome Xp21.1-p11.22. Mutation screening of
the NDP gene identified a novel nonsense mutation, c.343C>T, in this region.
Conclusions: Although recent research has shown that multiple different mutations can be responsible for the ND
phenotype, additional research is needed to understand the mechanism responsible for the diverse phenotypes caused by
mutations in the NDP gene.
Norrie disease (ND; OMIM 310600), a rare X-linked
recessive disorder, is characterized by congenital blindness
and,  occasionally,  mental  retardation  and  hearing  loss.
Degenerative and proliferative changes are observed in the
neuroretina of ND patients and lead to early-onset blindness.
More complex phenotypes are included in some ND cases,
such as microphthalmia, growth failure, and seizures [1,2].
ND is caused by mutations in the NDP gene, which is located
on chromosome Xp11.1. The NDP gene contains three exons,
but only the second and the third exons are translated [3].
Norrin—a 133-amino acid protein encoded by the NDP gene
—plays a critical role in the norrin-FZD4 signaling system,
which is involved in the vascular development of the eye and
ear [4]. More than 75 disease-causing mutations have been
identified in ND patients [5-9]. Lack of norrin expression,
truncated  norrin,  or  mutations  affecting  the  Cys  residues
involved in the conserved motif are much more likely to cause
ND. However, the mechanism responsible for the variety of
effects caused by norrin mutants is not entirely clear.
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Here, we report a family possessing a novel nonsense
mutation  in  the  NDP  gene,  accompanied  by  severe
presentation of ND in the three affected male patients. This is
the first report of a Chinese family with three affected males
with the NDP mutation. The proband is a 20-year-old male
afflicted with symptoms typical of ND, including blindness,
epileptic seizures, and degenerative neuropathy characterized
by mental retardation. A computed tomography (CT) scan of
his brain indicated remarkable cerebellar atrophy and the fifth
ventricle between the left and right transparent septum, which
is not common in human brains.
METHODS
The 26 patients studied here comprise three generations of a
Chinese family from Shandong Province. The proband, III:5,
was born in 1989 after a normal pregnancy. When he was two
months old, he was sent to a local hospital where he was
diagnosed  with  congenital  cataracts.  His  medical  record
described the following characteristics: cloudy cornea in both
eyes, lens opacities, leukoplakia of the cornea in both eyes,
and posterior synechiae in the left eye. The right pupil could
not be seen, and the diameter of the left pupil was 2 mm. In
2008,  the  proband  and  his  two  affected  relatives  were
examined in further detail, and a CT scan of the proband’s
brain  was  performed.  Considering  the  possibility  of
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2653haploinsufficiency,  a  magnetic  resonance  imaging  (MRI)
scan of the carrier III:6’s brain was performed as well.
Genomic DNA was extracted from the peripheral blood
using the standard phenol/chloroform method and was stored
at −20 °C. The study complied fully with the Tenets of the
Declaration of Helsinki and was confirmed by the Ethics
Board of the State Key Laboratory of Medical Genetics of
China. Informed consent was given by all members of the
family before testing. Because the proband was unable to
communicate with us, his informed consent was obtained
from his parents.
Microsatellite DNA markers were mapped to genes on
the X chromosome by polymerase chain reaction (PCR) with
17  fluorescent  microsatellite  markers  (ABI  prism  linkage
mapping  set  version  2.5:  DXS1060,  DXS8051,  DXS987,
DXS1214, DXS1068, DXS993, DXS991, DXS986, DXS990,
DXS1106,  DXS8055,  DXS1001,  DXS1047,  DXS1227,
DXS8043, DXS8091, and DXS1073). To perform the PCR,
a  calculated  master  mix  was  created  and  then  divided  to
several tubes equally. Each tube’s ingredients were 50 ng
genomic template DNA, 0.5 μl PCR 10× buffer, 0.1 μl dNTP
mix (2.5 mM), 0.06 μl each of forward and reverse primers,
0.6  μl  MgCl2  (15  mM),  and  0.05  U  of  AmpliTaq  Gold
(Applied  Biosystems,  Foster  City,  CA);  the  solution  was
brought to 5 μl with deionized water. Thermal cycling was
conducted as follows: 95 °C for 12 min; 15 cycles of 94 °C
for 30 s, 63 °C for 1 min with a decrease of 0.5 °C per cycle,
and 72 °C for 1 min 50 s; 24 cycles of 94 °C for 30 s, 56 °C
for 1 min, and 72 °C for 1 min 50 s; and a final extension step
of 72 °C for 15 min (GeneAmp 2720, Applied Biosystems).
PCR products were analyzed on an ABI 3100 automated
sequencer  (Applied  Biosystems).  GS400  was  used  as  an
internal size standard and was run in the same lane as the
markers.  GENESCAN  and  GENOTYPER  software  were
used to determine the size of the alleles. Subsequently, an
additional 12 fluorescent markers from the Human Genome
Database and Marshfield Database were analyzed for fine-
scale mapping (DXS8090, DXS8015, DXS8012, DXS8085,
DXS8035,  DXS8080,  DXS8054,  DXS8083,  DXS1003,
DXS1039, DXS988, and DXS1204).
Two-point LOD scores were computed with the MLINK
linkage analysis program (by Jurg Ott, version 5.2) [10]. All
linkage analyses were performed using an X-linked recessive
inheritance model with full penetrance in homozygotes and
hemizygous males and a disease-allele frequency of 0.0001.
Map distances were taken from the Marshfield Database, and
haplotypes were manually reconstructed.
Mutation  screening  of  the  NDP  gene,  for  all  family
members and for 100 healthy volunteers as normal controls,
was performed in conjunction with X chromosome scans.
PCR was used to amplify the region spanning exon 2 (forward
primer: 5′-ATC CTG CCC TTT CCT TGA; reverse primer:
5′-AGC CTC ATT CTC CCA CAA), and exon 3 (forward
primer:  5′-TGA  GCC  ACT  GGT  CTA  ATC  TA;  reverse
primer: 5′-CTC TCT CTG TCA ACA AGC AT) of the NDP
gene.  To  perform  the  PCR,  a  calculated  master  mix  was
created and then divided to several tubes equally. Each tube’s
ingredients were 1 μl (50 ng) genomic DNA, 1 μl (30 ng) of
each  primer,  1  μl  10×  PCR  buffer  with  MgCl2  (Roche
Diagnostics Corporation, Indianapolis, IN), 0.05 μl (5 U) of
AmpliTaq  Gold  (Applied  Biosystems);  the  solution  was
brought to 10 μl with deionized water. The PCR products were
purified  with  shrimp  alkaline  phosphatase  (Fermentas
International  Inc.,  Burlington,  Ontario,  Canada)  and
exonuclease I (Fermentas) for 90 min at 37 °C to remove the
phosphoryl  groups.  The  samples  were  sequenced  on  an
automated  sequencer  in  both  directions  according  to  the
manufacturer’s recommendations (ABI PRISM 3100 Genetic
Analyzer, Applied Biosystems).
RESULTS
Clinical findings: Three males from the Chinese family—the
proband,  his  uncle,  and  his  cousin—are  affected  by  the
disease, indicating that it might be inherited in an X-linked
recessive manner.
Figure 1. The proband, III:5, and his left
eye. Cloudy cornea in both eyes, lens
opacities, leukoplakia of the cornea in
both eyes, and posterior synechiae in the
left  eye  were  observed.  Further,  the
patient  was  suffered  by  seizures  and
mental disorders. The features of rolled
up eyes and dribbling can be observed
in this image.
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2654Results of visual acuity examination of the proband were:
no light perception in either eye, bilateral adherent leucoma
of cornea, congenital cataract (Figure 1). Because the proband
had  severe  mental  retardation  and  epilepsy,  the  anterior
chamber  and  posterior  segment  of  his  eye  could  not  be
examined. A B-ultrasonic scan showed that the optic axes are
21 mm in the right eye and 20 mm in the left eye and vitreous
opacity. No retinal detachment was found.
A CT scan of the proband’s brain (Figure 2) indicated that
he  had  experienced  cerebellar  atrophy  with  widened  and
deepened sulci; the fifth ventricle was also observed on the
scan. Cerebral density remained normal; no widening and
deepening of the cerebral sulcus fracture were found; and the
position of central structure had not changed.
The other two patients were also afflicted by epilepsy and
progressive mental disorders, and can barely communicate
with other people. Even with assistance, they are barely able
to walk; however, they are more mobile than the proband, who
can only be moved in a wheelchair. The conditions of all three
patients have worsened with age.
No ND phenotype was found in the carriers. The MRI
scan of carrier III:6’s brain showed no abnormality (Figure 2).
Linkage  analysis:  The  maximum  LOD  score  for  all  17
analyzed  markers  was  1.51  for  DXS993  on  chromosome
Xq11.4. On the basis of this result, we analyzed 12 additional
fluorescent markers in the flanking regions of DXS993 for
fine-scale  mapping.  Of  these,  10  yielded  additional
information; three of these markers (DXS8012, DXS8035,
and DXS1003) had LOD scores greater than 2 (Table 1),
which suggested that they were involved in the ND phenotype.
Haplotype  analysis  and  recombination  mapping:  All  12
fluorescent  microsatellite  markers  flanking  DXS993  were
used to construct the haplotypes. Inspection of the haplotype
transmission  data  (Figure  3)  showed  a  telomeric
recombination  event  between  markers  DXS8090  and
DXS8015 in individuals II:8 and III:1, placing the disease-
causing  gene  centromeric  to  marker  DXS8090.  Similarly,
recombination events between loci DXS1039 and DXS988
occurred in individuals II:10 and II:12, indicating that the
disease gene is telomeric to locus DXS988. Thus, in this
family, the disease gene lies within a 15.71-cM region on
chromosome Xp21.1-p11.22, bounded proximally by locus
DXS8090 and distally by locus DXS988.
Figure 2. The CT scan and MRI scan
results.  A:  CT  scan  of  the  proband’s
brain;  these  images  show  cerebellar
atrophy  with  widened  and  deepened
sulci and permit observation of the fifth
ventricle.  Arrows  show  cerebellar
atrophy  is  characterized  by  narrowed
lobes and widened folds of cerebellar
hemisphere  and  vermis;  and  the
evolution  of  the  cavity  of  septum
pellucidum. B: MRI scan of carrier III:
6’s brain; no abnormality was observed.
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2655Mutation screening: The three affected patients (II:3, III:1,
and III:5) were homozygous for a novel nonsense mutation,
c.343C>T; four other individuals (I:2, II:2, II:5, and III:6)
were  heterozygous  for  this  genotype  (Figure  4).  This
transition causes an Arg115Term exchange and results in the
production of a nonfunctional truncated norrin protein. The
distribution  of  carriers  and  non-carriers  in  this  pedigree
conforms to the predictions of the haplotype analysis and
recombination  mapping.  The  c.343C>T  mutation  was  not
found in the controls.
DISCUSSION
ND is rarely reported in China. Here, we have used CT scans,
genome  scans,  and  mutation  screening  to  confirm  the
characteristics  of  ND  and  diagnose  ND  according  to
Warburg’s criteria [11]. Mental disturbances have also been
described in other ND patients [12,13]. However, previous
reports  did  not  describe  motor  disorders  or  cerebellar
atrophies as severe as those documented here. These results
may provide more data for research and molecular diagnosis
of the disease.
TABLE 1. TWO-POINT LOD SCORES FOR MICROSATELLITE DNA MARKERS.
    Recombination fraction  
Marker cM
0.00 0.1 0.2 0.3 0.4 0.5
DXS8090 36.79 -∞ 0.09 0.33 0.29 0.14 0.00
DXS8015 37.87 0.90 0.77 0.61 0.44 0.24 0.00
DXS8012 42.21 2.41 2.00 1.54 1.02 0.45 0.00
DXS993 42.21 1.51 1.23 0.92 0.58 0.21 0.00
DXS8085 42.75 0.90 0.77 0.61 0.44 0.24 0.00
DXS8035 43.83 2.41 2.00 1.54 1.02 0.45 0.00
DXS8054 45.87 1.51 1.23 0.92 0.58 0.21 0.00
DXS8083 46.54 1.51 1.23 0.92 0.58 0.21 0.00
DXS1003 47.08 2.41 2.00 1.54 1.02 0.45 0.00
DXS988 52.50 -∞ 0.09 0.36 0.35 0.22 0.00
DXS1204 52.50 -∞ 0.09 0.36 0.35 0.22 0.00
Figure 3. Pedigree of the study family
and  the  haplotypes  obtained  from
examining  12  microsatellite  DNA
markers  on  chromosome  X.  Solid
symbols represent affected individuals
and open symbols represent unaffected
individuals. The arrowhead denotes the
proband.  Markers  are  listed  in  order
from  the  centromere  to  the  telomere.
The  affected  haplotype  is  shown  in
rectangles.
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2656The NDP gene maps to Xp11.1, spans 28 kb, and contains
3  exons.  Exon  1of  the  NDP  gene  contains  only  the  5′
untranslated region; the first 58 residues of the open reading
frame are in exon 2, while codons 59–133 of the open reading
frame and the 3′ untranslated region are in exon 3 [3]. ND is
ascribed to mutations of the NDP gene, which can also cause
X-linked  familial  exudative  vitreoretinopathy  (XL-FEVR)
[14-16]. XL-FEVR is a heterogeneous vitreoretinal disorder
characterized by peripheral vitreous opacities, subretinal and
intraretinal exudates, and retinal traction due to failure of
peripheral retinal vascularization [17].
NDP encodes norrin, a member of the cystine knot growth
factor family [18]. It is a secreted cysteine-rich protein that
has 133 amino acids. The cystine knot domain of norrin spans
from codon 32 to codon 133, which is thought to play an
essential role in neurologic interactions [19]. The cysteine
residues at codons 39, 65, 69, 96, 126, and 128 have been
found to be responsible for the cysteine-knot formation. Three
disulfide bridges between codon 39 and 96, 65 and 126, and
69 and 128 are involved in the tertiary structure of norrin [5].
Most mutations of the NDP gene associated with ND or XL-
FEVR  are  related  to  this  domain,  including  R115L  (c.
344G>T) and R109Term (c.325C>T), which cause XL-FEVR
and ND, respectively [20]. Thus far, all patients with nonsense
mutations were diagnosed with ND disease.
The novel mutation in exon 3 at codon 115 altered the
arginine codon to a termination codon. Hence, the last 18
amino acids of the wild-type norrie protein would lost by the
resulting  protein,  which  contains  cysteine  residues  and
disulfide  bridges  involved  in  the  cysteine  knot.  The
R115Term  mutation  might  considerably  alter  the  protein
structure and severely disrupt neurologic interactions related
to the cystine knot domain.
The function of norrin is not entirely clear; however,
research has shown that it may be involved in the development
of  the  neuroectoderm  or  in  regulation  of  neural  cell
proliferation [21]. Norrin has been identified as a specific
ligand for frizzled-4 (FZD4; OMIM 604579), a presumptive
Wnt  receptor.  Interacting  with  the  cysteine-rich  domain
(CRD)  of  FZD4,  norrin  can  activate  the  Wnt/β-catenin
pathway  by  inducing  FZD4-  and  LRP  (OMIM  107770)-
dependent activation, affecting vascular development in the
ear and eye [4]. Moreover, norrin plays an important role in
retinal vasculogenesis and in neural cell differentiation and
proliferation [22,23]. Additionally, evidence has shown that
the neuroprotective properties of norrin are independent from
its effects in vascular development [24]. This may explain
why degenerative neuropathies such as seizures and mental
disorders were observed in the affected individuals examined
in this study.
However,  the  mechanism  by  which  mutations  in  the
NDP  gene  cause  the  complex  phenotypes  of  ND  is  still
unclear. Further, the case presented here supports Schuback’s
assumption that new phenotypic expressions of the disease
may  be  identified  [6].  This  may  result  from  complex
epigenetic factors that interact and influence the physiologic
and  neurodevelopmental  expression  of  the  ND  phenotype
[6]. More data are required to further the understanding of the
diverse and variable effects of norrin mutations.
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